Browsing by Subject "Exercise tolerance"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    Identifying COPD patients with poor health status and low exercise tolerance through the five-repetition sit-to-stand test and modified Medical Research Council Dyspnea Score
    (Elsevier, 2024-07-01) Bernabeu Mora, Roberto; Oliveira Sousa, Silvana Loana de; Medina i Mirapeix, Francesc; Gacto Sánchez, Mariano Luis; Fisioterapia
    Background: The objective of this study was to determine whether the concomitant presence of poor health status (COPD Assessment Test, CAT ≥ 10 points) and low exercise tolerance (6-Minute Walking Test, 6MWT < 350 m) is associated with worse clinical characteristics in patients with COPD. In addition, we aimed to develop a readily applicable diagnostic model to discriminate COPD patients with these conditions. Methods: A cross-sectional multicenter study involving 208 stable COPD patients (FEV1/FVC < 0.7, smoking history of at least 10 pack-years, and chronic respiratory symptoms) was carried out. The outcome measures were the 6MWT, CAT score, 5-repetition sit-to-stand test (5STS) and modified Medical Research Council Dyspnea Scale (mMRC). Patients were categorized into three groups: no condition (6MWT ≥ 350 m and CAT < 10 points), one condition (6MWT < 350 m or CAT ≥ 10 points), and both conditions (6MWT < 350 m and CAT ≥ 10 points). Results: A total of 26 patients (12,5%) presented both conditions. These patients experienced a higher degree of dyspnea (p = 0.001), smoking pack-years (p = 0.011), severe obstruction (p = 0.006), and time on 5STS (p = 0.001). The probability of having both conditions directly increased with the time spent on the 5STS (β=0.188; p = 0.010) and the degree of dyspnea (β=1.920; p < 0.001) (R2=0.413). The scoring system, using the 5STS and dyspnea as surrogate measures, demonstrated adequate calibration between the predicted and observed risk (linear R2=0.852). Conclusions: COPD patients with concurrent conditions have worse clinical status. The diagnostic model developed to discriminate these patients shows good internal validation.
  • Thumbnail Image
    Publication
    Open Access
    La fotobiomodulación puede aumentar la tolerancia al ejercicio y la activación de los músculos del antebrazo en hombres sanos: un estudio cruzado, aleatorizado y controlado con placebo
    (Universidad de Murcia: servicio de publicaciones, 2025) Zago, Julio; Santos, Francisco Valdez; Vieira, Paulo, J.C; Rondinel, Tatiana; Diefenthaeler, Fernando; Machado, Sergio; Aprigliano, Vicente; Silva, Weder Alves; Inacio, Pedro Augusto; Sá Filho, Alberto; Chiappa, Gaspar R.; Sin departamento asociado
    Despite the positive effects of photobiomodulation (PBM) on muscle behavior, its effects on exercise tolerance and reactive hyperemia (RH) are poorly understood. Objective: assess the acute effects of PBM with 904 and 660, nm wavelengths irradiated at the forearm flexor muscles on exercise tolerance through the analysis of RH and muscle activation. This preliminary, double-blind, placebo-controlled crossover trial was performed with 11 healthy participants. We randomly applied PBM 904nm, PBM 660nm, and placebo at six different points at the dominant flexor muscle area. The placebo group received the stimulation at the same points with a turned-off device. RH was assessed by measuring forearm blood flow which was calculated using the peak blood flow after the 5-min occlusion with the technique of venous occlusion plethysmography. Electromyography was assessed through surface electrodes on three flexor forearm muscles. The root mean square (RMS) and median frequency (MDF) were plotted at 25, 50, 75, and 100% of the limit of tolerance (Tlim). PBM 660 irradiation significantly increased RH when compared to PBM 904 and placebo. Furthermore, PBM 660 and 904 increased RMS and reduced MDF when compared to placebo. PBM 660 irradiation was superior to 904 and placebo in the increase of RH but the application of both irradiations was similar in the activation of forearm muscles in healthy men. Trial registration: www.ensaiosclinicos.gov.br RBR-7yspdx